The healthcare industry is poised for significant advancements in the upcoming year, with AI adoption, increased startup exits, and ongoing regulatory challenges at the forefront. A recent survey of healthcare executives by Deloitte and research from PitchBook indicate that AI technology will revolutionize drug discovery, potentially doubling the number of drugs that successfully make it through clinical trials while reducing costs and timelines. Additionally, AI is expected to streamline administrative tasks for healthcare professionals, making processes more efficient.
Looking ahead to 2026, there is a strong emphasis on M&A activity in the biotech and medtech sectors. Notable deals, such as Johnson & Johnson’s acquisition of Intra-Cellular Therapies and Pfizer’s purchase of Metsera, highlight the strategic importance of partnerships and acquisitions in the industry. Regulatory uncertainty remains a key concern for healthcare executives, with potential policy changes on the horizon that could impact Medicare reimbursements, insurance underwriting, and other aspects of the industry.
Trade tensions, particularly with China, are also a significant challenge for medtech companies, with the possibility of increased tariffs on medical devices in the coming year. Despite these obstacles, the healthcare industry is poised for growth and innovation in 2026.
In other news, French health tech unicorn Doctolib is in talks to secure a large secondary investment, potentially worth hundreds of millions of dollars. The company, which reached a valuation of $6.4 billion earlier this year, is looking to further solidify its position in the market with this new funding round.
On a somber note, the healthcare industry recently lost a pioneering figure with the passing of Alice Schwartz, cofounder of Bio-Rad. Schwartz played a crucial role in the company’s early years, helping to develop its first test kit for thyroid function and guiding its growth into a leading provider of clinical diagnostics products. Her legacy as a trailblazing woman in healthcare will be remembered for years to come.
In the world of biotech, Chai Discovery recently announced a significant funding round of $130 million, led by Oak HC/FT and General Catalyst. The company, which specializes in computer-designed proteins, has seen its valuation soar to $1.3 billion, showcasing the growing interest in AI-driven drug discovery technologies.
As we close out the year, it’s clear that the healthcare industry is on the brink of transformative changes. From AI advancements to major investment deals, the coming year promises to be a dynamic and exciting time for the sector. Stay tuned for more updates and developments in 2026.
